[go: up one dir, main page]

AR077240A1 - Sulfonamidas heterociclicas, composiciones farmaceuticas de la mismas y su uso en trastornos neurologicos. - Google Patents

Sulfonamidas heterociclicas, composiciones farmaceuticas de la mismas y su uso en trastornos neurologicos.

Info

Publication number
AR077240A1
AR077240A1 ARP100102268A ARP100102268A AR077240A1 AR 077240 A1 AR077240 A1 AR 077240A1 AR P100102268 A ARP100102268 A AR P100102268A AR P100102268 A ARP100102268 A AR P100102268A AR 077240 A1 AR077240 A1 AR 077240A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently selected
cycloalkyl
heterocycloalkyl
heteroaryl
Prior art date
Application number
ARP100102268A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43127233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR077240(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of AR077240A1 publication Critical patent/AR077240A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/07—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula 1, o una sal farmacéuticamente aceptable del mismo, en la que cada R1, cada R2 y cada R7 se selecciona independientemente entre el grupo constituido por hidrogeno, halogeno, hidroxilo, -CF3, -CN, -C(=O)R8, -O-(C=O)-R8, -(NR8)-(C=O)-R8, -(CO)-OR8, -(C=O)-N(R8)2, -OR8, -O(C=O)-OR8, -O-(C=O)-N(R8)2, -NO2, -N(R8)2, -(NR8)-SO2-R8, -S(O)wR8, -SO2(R8)2, alquilo C1-6, arilo C6-10, heteroarilo C1-9, heterocicloalquilo C1-9 y cicloalquilo C3-10; en los que cada uno de dichos alquilo C1-6, arilo C6-10, heteroarilo C1-9, heterocicloalquilo C1-9 o cicloalquilo C3-10 está opcionalmente sustituido independientemente con uno, dos, tres o cuatro R9; w es 0, 1 o 2; m es cero, uno, dos o tres; n es cero, uno, dos o tres; p es cero, uno, dos o tres; q es cero, uno, dos o tres; s es uno y t es uno; o uno de s o t es uno y el otro de s o t es dos; R3 es hidrogeno o alquilo C1-6; cada R4 se selecciona independientemente entre hidrogeno o alquilo C1-6; en los que dicho alquilo C1-6 puede estar opcionalmente sustituido con uno, dos, tres o cuatro halogenos, -CN, o -OR9; o dos grupos R4 sobre el mismo átomo de carbono pueden tomarse juntos para formar un radical oxo (=O) o un espirocicloalquilo C3-6; R5 es hidrogeno o alquilo C1-6; R6 es alquil C1-6-(C=O)-, [alquil C1-6]2N-(C=O)-alquil C1-6-SO2-, cicloalquil C3-10-SO2- o [alquil C1-6]2N-SO2-; donde dichos restos alquilo C1-6 de dicho [alquil C1-6]2N-(C=O)- y [alquil C1-6]2N-SO2- pueden tomarse opcionalmente junto con el átomo de nitrogeno al que están unidos para formar un anillo heterocíclico de cuatro a seis miembros; R8 se selecciona independientemente entre el grupo constituido por hidrogeno, alquilo C1-6, arilo C6-10, heteroarilo C1-9, heterocicloalquilo C1-9 y cicloalquilo C3-10; en los que dicho alquilo C1-6 puede estar opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados independientemente entre hidrogeno, halo, -CN, perfluoroalquilo C1-6, hidroxi, amino, alquilamino C1-6, [alquil C1-6]2amino, alcoxi C1-6, perfluoroalcoxi C1-6, HO-(C=O)-, alquil C1-6-O-(C=O)-, formilo, alquil C1-6-(C=O)-, H2N-(C=O)-, alquil C1-6-(NH)-(C=O)-, [alquil C1-6]2N-(C=O)-, alquil C1-6-(C=O)-O-H(C=O)-NH-, alquil C1-6-(C=O)-NH-, alquil C1-6-(C=O)-[N(alquil C1-6)]-, alquil C1-6-SO2-, alquil C1-6-SO2-NH-, alquil C1-6-SO2-[N(alquil C1-6]-, H2N-SO2-, [alquil C1-6]-NH-SO2- y [alquil C1-6]2N-SO2-; en los que dicho alquilo C1-6 puede estar opcionalmente sustituido adicionalmente con un opcionalmente sustituido arilo C6-10, heteroarilo C1-9, heterocicloalquilo C1-9 o cicloalquilo C3-10; en los que dichos sustituyentes opcionales pueden seleccionarse independientemente entre uno, dos, tres o cuatro radicales seleccionados independientemente entre halogeno, hidroxilo, -CF3, -CN, alquilo C1-3, alcoxi C1-3 y amino; en los que cada uno de dichos sustituyentes R8 arilo C6-10, heteroarilo C1-9, heterocicloalquilo C1-9 o cicloalquilo C3-10 puede estar opcionalmente sustituido adicionalmente con uno, dos, tres o cuatro radicales seleccionados independientemente entre halogeno, hidroxilo, -CF3, -CN, alquilo C1-3, alcoxi C1-3 y amino; cada R9 se selecciona independientemente entre el grupo constituido por halogeno, hidroxilo, -CF3, -CN, -(C-O)R10, -O-(C=O)-R10, -(NR10)-(C=O)-R10, -(C-O)-OR10, -(C=O)-N(R10)2, -OR10, -O-(C=O)-OR10, -O-(C=O)-N(R10)2, -NO2, -N(R10)2, -(NR10)-SO2-R10, -S(O)wR10, -SO2-N(R10)2; R10 se selecciona independientemente entre el grupo constituido por hidrogeno, alquilo C1-6, arilo C6-10, heteroarilo C1-9, heterocicloalquilo C1-9 y cicloalquilo C3-10; en el que dicho alquilo C1-6 puede estar opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados independientemente entre hidrogeno, halo, -CN, perfluoroalquilo C1-6, hidroxi, amino, alquilamino C1-6, [alquil C1-6]2amino, alcoxi C1-6, perfluoroalcoxi C1-6, HO-(C=O)-, alquil C1-6-O-(C-O)-, formilo, alquil C1-6-(C=O)-, H2N-(C=O)-, alquil C1-6-(NH)-(C=O)-, [alquil C1-6]2N-(C=O)-, alquil C1-6-(C=O)-O-, H(C=O)-NH-, alquil C1-6-(C=O)-NH-, alquil C1-6-(C=O)-[N(alquil C1-6)]-, alquil C1-6-SO2-, alquil C1-6-SO-NH-, alquil C1-6-SO2-[N(alquilo C1-6)]-, H2N-SO2-, [alquil (C1-6)]-NH-SO2- y [alquil C1-6]2N-SO2-; en los que dicho alquilo C1-6 también puede estar opcionalmente sustituido adicionalmente con un arilo C6-10, heteroarilo C1-9, heterocicloalquilo C1-9 o cicloalquilo C3-10 opcionalmente sustituido; en los que dichos sustituyentes opcionales pueden seleccionarse independientemente entre uno, dos, tres o cuatro radicales seleccionados independientemente entre halogeno, hidroxilo, -CF3, -CN, alquilo C1-3, alcoxi C1-3 y amino; en los que cada uno de dichos sustituyentes R10 arilo C6-10, heteroarilo C1-9, heterocicloalquilo C1-9 o cicloalquilo C3-10 puede estar opcionalmente sustituido adicionalmente con uno, dos, tres o cuatro radicales seleccionados independientemente entre halogeno, hidroxilo, -CF3, -CN, alquilo C1-3, alcoxi C1-3 y amino; R11 es hidrogeno o alquilo C1-6; el anillo ôAö es arilo C6-10, heteroarilo C1-9, cicloalquilo C4-10 o heterocicloalquilo C1-9; en los que dos de dichos sustituyentes R1 sobre dicho cicloalquilo C4-10 y heterocicloalquilo C1-9 pueden estar unidos opcionalmente al mismo átomo de carbono y pueden tomarse opcionalmente juntos para que sean oxo; el anillo ôBö es arilo C6-10, heteroarilo C1-9, cicloalquilo C4-10 o heterocicloalquilo C1-9; ôXö es -O- o >C(R4)2; ôYö está ausente o es >NR11, -(NR11)-(CO)-, >C=O, -O- o >C(R7)2; y ôZö es -O-, -S-, -(S=O)- o -(SO2)-.
ARP100102268A 2009-06-26 2010-06-25 Sulfonamidas heterociclicas, composiciones farmaceuticas de la mismas y su uso en trastornos neurologicos. AR077240A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22062509P 2009-06-26 2009-06-26

Publications (1)

Publication Number Publication Date
AR077240A1 true AR077240A1 (es) 2011-08-10

Family

ID=43127233

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102268A AR077240A1 (es) 2009-06-26 2010-06-25 Sulfonamidas heterociclicas, composiciones farmaceuticas de la mismas y su uso en trastornos neurologicos.

Country Status (42)

Country Link
US (7) US8278457B2 (es)
EP (1) EP2445883B1 (es)
JP (1) JP5079933B1 (es)
KR (1) KR101401886B1 (es)
CN (1) CN102471271B (es)
AP (1) AP3066A (es)
AR (1) AR077240A1 (es)
AU (1) AU2010264095B2 (es)
BR (2) BR122019013104B1 (es)
CA (1) CA2766104C (es)
CL (1) CL2011003302A1 (es)
CO (1) CO6480931A2 (es)
CR (1) CR20110680A (es)
CU (1) CU24078B1 (es)
DK (1) DK2445883T3 (es)
DO (1) DOP2011000382A (es)
EA (1) EA021057B1 (es)
EC (1) ECSP11011555A (es)
ES (1) ES2517267T3 (es)
GE (1) GEP20146014B (es)
GT (1) GT201100336A (es)
HN (1) HN2011003403A (es)
HR (1) HRP20140867T1 (es)
IL (1) IL217083A (es)
MA (1) MA33384B1 (es)
ME (1) ME01903B (es)
MX (1) MX2011013884A (es)
MY (1) MY165918A (es)
NI (1) NI201100218A (es)
NZ (1) NZ597226A (es)
PE (1) PE20120329A1 (es)
PL (1) PL2445883T3 (es)
PT (1) PT2445883E (es)
RS (1) RS53626B1 (es)
SG (1) SG176828A1 (es)
SI (1) SI2445883T1 (es)
TN (1) TN2011000654A1 (es)
TW (1) TWI388558B (es)
UA (1) UA102310C2 (es)
UY (1) UY32736A (es)
WO (1) WO2010150192A1 (es)
ZA (1) ZA201200367B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013003101A (es) 2010-09-17 2013-09-26 Purdue Pharma Lp Compuestos de piridina y sus usos.
EP2655330B1 (en) * 2010-12-22 2016-02-10 Purdue Pharma LP Substituted pyridines as sodium channel blockers
EP2694472B1 (en) * 2011-04-05 2020-03-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
EP3601267A1 (en) 2017-03-21 2020-02-05 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds
CA3097231A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
NZ787541A (en) 2019-11-25 2025-10-31 Alkermes Inc Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
AR129265A1 (es) 2022-05-12 2024-08-07 Syngenta Crop Protection Ag Compuestos de alcoxi-heteroaril-carboxamida o tioamida
CA3260217A1 (en) * 2022-06-21 2023-12-28 Alkermes, Inc. SUBSTITUTED PYRROLIDINYL AND PIPERIDINYL COMPOUNDS AND ASSOCIATED TREATMENT METHODS
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
CN120476107A (zh) 2022-12-15 2025-08-12 先正达农作物保护股份公司 可用作杀有害生物剂的新型的二环-甲酰胺化合物
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
WO2025032129A1 (en) 2023-08-08 2025-02-13 Syngenta Crop Protection Ag Novel aminoindane and aminotetraline compounds
WO2025104032A1 (en) 2023-11-14 2025-05-22 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149629A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1101755B1 (en) * 1998-07-24 2004-10-06 Teijin Limited Anthranilic acid derivatives
EP1296944A1 (en) 2000-05-19 2003-04-02 Eli Lilly And Company Sulfonamide derivatives
EA200201233A1 (ru) 2000-05-19 2003-04-24 Эли Лилли Энд Компани Способ получения бифенильных соединений
US6673802B2 (en) * 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
JP2010517926A (ja) * 2006-02-08 2010-05-27 グラクソ グループ リミテッド グルタミン酸受容体を増強する、統合失調症の治療に有用な４−フェニル−３−（２−プロピルスルホニルアミノ）テトラヒドロフラン誘導体
GB0801220D0 (en) * 2008-01-23 2008-02-27 Glaxo Group Ltd Compounds
US20110172297A1 (en) * 2008-10-02 2011-07-14 Pfizer Inc Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof
US20110178165A1 (en) * 2008-10-08 2011-07-21 Pfizer Inc. Tetrahydrofuranyl sulfonamides and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
SG176828A1 (en) 2012-01-30
TW201103923A (en) 2011-02-01
EA201190320A1 (ru) 2012-06-29
PT2445883E (pt) 2014-10-27
CR20110680A (es) 2012-02-02
RS53626B1 (sr) 2015-04-30
HN2011003403A (es) 2015-01-26
GEP20146014B (en) 2014-01-27
MA33384B1 (fr) 2012-06-01
ZA201200367B (en) 2012-11-28
AP3066A (en) 2014-12-31
US20120322823A1 (en) 2012-12-20
MX2011013884A (es) 2012-02-01
EP2445883A1 (en) 2012-05-02
CN102471271A (zh) 2012-05-23
AU2010264095B2 (en) 2013-07-11
US20140323502A1 (en) 2014-10-30
IL217083A0 (en) 2012-02-29
TN2011000654A1 (fr) 2013-05-24
ES2517267T3 (es) 2014-11-03
SI2445883T1 (sl) 2014-10-30
AP2012006072A0 (en) 2012-02-29
PE20120329A1 (es) 2012-04-04
NZ597226A (en) 2013-04-26
US20110105533A1 (en) 2011-05-05
WO2010150192A1 (en) 2010-12-29
CA2766104A1 (en) 2010-12-29
DOP2011000382A (es) 2012-02-29
US20170247360A1 (en) 2017-08-31
ME01903B (me) 2014-12-20
JP2012531398A (ja) 2012-12-10
US20190100491A1 (en) 2019-04-04
DK2445883T3 (da) 2014-10-13
KR101401886B1 (ko) 2014-05-29
CA2766104C (en) 2015-01-27
IL217083A (en) 2016-08-31
CL2011003302A1 (es) 2012-07-13
CU20110233A7 (es) 2012-03-15
GT201100336A (es) 2015-06-02
US8686043B2 (en) 2014-04-01
BR122019013104B1 (pt) 2021-07-13
US20160272625A1 (en) 2016-09-22
UA102310C2 (ru) 2013-06-25
AU2010264095A1 (en) 2012-01-19
HRP20140867T1 (hr) 2014-10-24
US8278457B2 (en) 2012-10-02
US20240051917A1 (en) 2024-02-15
PL2445883T3 (pl) 2014-12-31
CN102471271B (zh) 2014-09-24
BRPI1014583A2 (pt) 2016-04-26
JP5079933B1 (ja) 2012-11-21
KR20120044348A (ko) 2012-05-07
NI201100218A (es) 2012-03-30
EA021057B1 (ru) 2015-03-31
MY165918A (en) 2018-05-18
CO6480931A2 (es) 2012-07-16
CU24078B1 (es) 2015-03-30
UY32736A (es) 2011-01-31
EP2445883B1 (en) 2014-08-13
ECSP11011555A (es) 2012-01-31
BRPI1014583B1 (pt) 2020-03-31
TWI388558B (zh) 2013-03-11

Similar Documents

Publication Publication Date Title
AR077240A1 (es) Sulfonamidas heterociclicas, composiciones farmaceuticas de la mismas y su uso en trastornos neurologicos.
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR079634A1 (es) Inhibidores del virus de la hepatitis c
AR092522A1 (es) Inhibidores de glucosilceramida sintasa
AR078609A1 (es) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros.
AR061548A1 (es) 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii.
AR094496A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR070558A1 (es) Derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino,proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de enfermedades dependientes de tirosinquinasas,tales como enfermedades proliferativas.
AR049170A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20231190A1 (es) Degradadores de moleculas pequenas de piperidinilo de helios y procedimientos de uso
AR034390A1 (es) Derivados de 1-sulfonil-tetrahidro quinolinas sustituidas, composiciones farmaceuticas y el uso de las mismas para la elaboracion de medicamentos como inhibidores de la gama secretasa
AR039659A1 (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa
AR062050A1 (es) Derivados de amina utiles como agentes anti-cancerigenos
AR070343A1 (es) Piridinil amidas, un procedimiento para el tratamiento de la esquizofrenia en un mamifero y una composicion farmaceutica
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR066013A1 (es) Derivados de oxazolidinona, composiciones farmaceuticas que los contienen y su uso en el tratamiento o prevencion de una infeccion bacteriana.
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
PE20161552A1 (es) Compuestos de dihidroisoquinolinona sustituida
AR073283A1 (es) Derivados de heteroarilamida y su uso como activadores de glucokinasa
AR044078A1 (es) Dihidroquinazolinas sustituidas
AR085489A1 (es) Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
CL2012000042A1 (es) Compuestos derivados de imidazo[1,2-a]pirazin-7-il; composición farmacéutica que comprende a uno de los compuestos; y uso de uno de los compuestos en la preparación de un medicamento útil para tratar una enfermedad relacionada con el género plasmodium en un sujeto.

Legal Events

Date Code Title Description
FG Grant, registration